Samalin Investment Counsel Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab US Dividend Equity ETF
SCHD
|
+$1.52M |
| 2 |
NVIDIA
NVDA
|
+$1.17M |
| 3 |
CVS Health
CVS
|
+$1.15M |
| 4 |
iShares Core 1-5 Year USD Bond ETF
ISTB
|
+$1.1M |
| 5 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$832K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.77M |
| 2 |
SPDR Gold Trust
GLD
|
+$1.35M |
| 3 |
Flex
FLEX
|
+$876K |
| 4 |
Cameco
CCJ
|
+$603K |
| 5 |
Procter & Gamble
PG
|
+$553K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 9.66% |
| 2 | Technology | 9.51% |
| 3 | Real Estate | 5.62% |
| 4 | Healthcare | 4.36% |
| 5 | Energy | 4.12% |
Similar funds
Samalin Investment Counsel's Q2 2026 Portfolio in Review
As of Q2 2026, Samalin Investment Counsel held 352 positions worth $320M, up 13% from $282M the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Samalin Investment Counsel deployed $12.4M of net new capital in Q2 2026, opening 33 new positions and adding to 150 existing holdings. Its largest new stake was CVS Health: 12,860 shares worth $1.33M.
By sector, the portfolio is most concentrated in Financials at 9.7% of assets, down from 10% a quarter earlier, followed by Technology and Real Estate.
On the sell side, the largest reduction was Micron Technology, an estimated $1.77M trimmed.
- Samalin Investment Counsel's largest Q2 2026 buy was CVS Health: 12,860 shares worth $1.33M.
- Samalin Investment Counsel added most to Schwab US Dividend Equity ETF in Q2 2026, an estimated $1.52M increase.
- Samalin Investment Counsel's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.77M.
- Samalin Investment Counsel fully exited Cameco in Q2 2026, selling an estimated $603K.
- Samalin Investment Counsel's ten largest holdings make up 19% of its $320M portfolio in Q2 2026.
- Samalin Investment Counsel opened 33 new positions and closed 16 in Q2 2026.
- Samalin Investment Counsel's portfolio value rose 13% quarter-over-quarter to $320M.
Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.